http://www.biocentury.com/rss/scibxSciBX: Science-Business eXchangeen-US© Copyright 2012 BioCentury, Inc.RSS Generatorhttp://www.biocentury.com/Data/NewsCenter2/Images/SciBX/CoverStory.gifhttp://www.biocentury.com/rss/scibxhttp://www.biocentury.com/scibx/coverstory/2012-05-10/cover-story-a-mind-for-precompetitive-collaboration-s1http://www.biocentury.com/scibx/coverstory/2012-05-10/cover-story-a-mind-for-precompetitive-collaboration-s1Cover StoryAlthough pharmas are cutting back on internal neuroscience R&D programs, the number of precompetitive consortia backed by industry continues to rise. Most initiatives are focused on developing better disease models and …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/coverstory/2012-05-10/selected-ongoing-precompetitive-neuroscience-industry-collaborations-s4http://www.biocentury.com/scibx/coverstory/2012-05-10/selected-ongoing-precompetitive-neuroscience-industry-collaborations-s4Cover StoryA mind for precompetitive collaboration Table 1. Selected ongoing precompetitive neuroscience industry collaborations. Initiative Research goals Industry partners Nonindustry partners Funding or organizing body…Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2012-05-10/targets-and-mechanisms-mitochondrial-gene-therapy-s6http://www.biocentury.com/scibx/targetsmechanisms/2012-05-10/targets-and-mechanisms-mitochondrial-gene-therapy-s6Targets & MechanismsA University of Miami team has used mitochondrion-targeted gene therapy to restore functional ND4 levels in Leber's hereditary optical neuropathy. Next steps include optimizing the approach to cover several variants of …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2012-05-10/targets-and-mechanisms-ppars-new-course-s8http://www.biocentury.com/scibx/targetsmechanisms/2012-05-10/targets-and-mechanisms-ppars-new-course-s8Targets & MechanismsCalifornia researchers have shown that agonizing PPARdelta could help stave off fibrosis in a variety of chronic liver diseases. The findings could open new therapeutic real estate for the handful of biotechs working on…Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16ahttp://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16aTechniquesApproach Summary Licensing status Publication and contact information Assays & screens Aptamer-based assay against secreted proteins for the identification of new cancer biomarkers An aptamer-based assay of …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16bhttp://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16bTechniquesApproach Summary Licensing status Publication and contact information Assays & screens Paper-based assay for reporting blood type as text A paper-based assay was used to identify and display blood type as text. …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16chttp://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16cTechniquesApproach Summary Licensing status Publication and contact information Computational models Algorithm for creating charged antibodies to improve stability and preserve activity In silico and in vitro studies …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16dhttp://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16dTechniquesApproach Summary Licensing status Publication and contact information Disease models Dopamine D2 receptor expression as a measure of Huntington's disease (HD) pathology Measuring dopamine D2 receptor expression …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16ehttp://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16eTechniquesApproach Summary Licensing status Publication and contact information Disease models Mice with working memory deficits as models of dementia-related delirium Mice with short-term deficits in working memory could…Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16fhttp://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16fTechniquesApproach Summary Licensing status Publication and contact information Disease models SH3 and multiple ankyrin repeat domains 2 (SHANK2)-deficient mouse model of autism spectrum disorder (ASD) Mice lacking Shank2…Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16ghttp://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16gTechniquesApproach Summary Licensing status Publication and contact information Drug delivery Acyclic cucurbit[n]urils as molecular containers to improve drug solubility Acyclic cucurbit[n]uril compounds may be useful as …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16hhttp://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16hTechniquesApproach Summary Licensing status Publication and contact information Drug platforms Gene therapy for Leber's hereditary optical neuropathy (LHON) Cell culture and mouse studies suggest a mitochondria-targeted …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16ihttp://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16iTechniquesApproach Summary Licensing status Publication and contact information Markers Epigenomic enhancer variants as biomarkers for colorectal cancer In vitro studies identified epigenomic markers that could be used as…Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16jhttp://www.biocentury.com/scibx/techniques/2012-05-10/the-distillery-techniques-s16jTechniquesApproach Summary Licensing status Publication and contact information Markers Genomic and expression analysis-derived breast cancer subgroups to predict response to therapy Genomic and expression analysis-…Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12ahttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12aTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Dedicator of cytokinesis 2 (DOCK2) In vitro and mouse studies identified a …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12bhttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12bTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) MicroRNA-301a (miR-301a) A study in mice suggests antagonizing miR-301a …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12chttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12cTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Hedgehog pathway; P glycoprotein (MDR1; ABCB1; P-gp; CD243) Mouse studies suggest P-gp …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12dhttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12dTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Autophagy In vitro and mouse studies suggest dimeric chloroquine analogs could help treat cancer more…Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12ehttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12eTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors Glucose-6-phosphate dehydrogenase (G6PD) An SAR study identified G6PD inhibitors that could be …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12fhttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12fTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors Tumor necrosis factor-a (TNF-a) Mouse studies suggest low-dose, recombinant TNF-a could be …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12ghttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12gTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes CD3; insulin (INS; proinsulin); IL-10 Studies in mice suggest Lactococcus …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12ihttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12iTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver fibrosis Peroxisome proliferation-activated receptor-d (PPARD; PPARd) Cell culture and mouse …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12jhttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12jTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair Peroxisome proliferation-activated receptor-g (PPARG; PPARGg) Mouse studies …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12khttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12kTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular dystrophy D4Z4 binding element transcript (DBE-T) Cell culture studies suggest …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12lhttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12lTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Tissue injury; muscular dystrophy MicroRNA-206 (miR-206) Mouse studies suggest agonizing …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12mhttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12mTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Graft-versus-host disease (GvHD) Not applicable Mouse studies suggest antibiotics could be useful …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12nhttp://www.biocentury.com/scibx/therapeutics/2012-05-10/the-distillery-therapeutics-s12nTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Various Cancer; inflammation Bromodomain containing 4 (BRD4) An in vitro study suggests the epigenetic target BRD4 …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/tools/2012-05-10/tools-dendrimers-get-cerebral-s10http://www.biocentury.com/scibx/tools/2012-05-10/tools-dendrimers-get-cerebral-s10ToolsU.S. researchers have developed a dendrimer-based therapy that reduced brain inflammation and improved the motor function of newborn rabbits with cerebral palsy. The team now needs to determine the therapy's treatment …Thu, 10 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/coverstory/2012-05-03/cover-story-heart-beats-fat-s1http://www.biocentury.com/scibx/coverstory/2012-05-03/cover-story-heart-beats-fat-s1Cover StoryUT Southwestern Medical Center researchers have discovered that knocking down microRNA-208a in the heart leads to systemic benefits in obesity and metabolic diseases. The findings could expand the potential indications…Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2012-05-03/targets-and-mechanisms-heat-shock-hits-muscular-dystrophy-s6http://www.biocentury.com/scibx/targetsmechanisms/2012-05-03/targets-and-mechanisms-heat-shock-hits-muscular-dystrophy-s6Targets & MechanismsAustralian academics have used N-Gene's BGP-15, a small molecule inducer of Hsp72, to increase muscle strength and survival in mice with muscular dystrophy. The biotech, which is testing the compound in Phase IIb for …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15ahttp://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15aTechniquesApproach Summary Licensing status Publication and contact information Assays & screens Microarray of modified RNAs to identify therapeutic RNAs against folded RNA targets A microarray displaying a library of …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15bhttp://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15bTechniquesApproach Summary Licensing status Publication and contact information Disease models Mice with humanized ectopic bone engraftments to test leukemia therapeutics Mice with humanized ectopic bone engraftments …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15chttp://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15cTechniquesApproach Summary Licensing status Publication and contact information Drug delivery Targeted delivery of small interfering RNA using single-chain variable antibody fragments (scFvs) Studies in mice suggest scFv-…Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15dhttp://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15dTechniquesApproach Summary Licensing status Publication and contact information Drug platforms Enzyme toolkit for replication of unnatural nucleic acids In vitro studies suggest engineered polymerases could enable …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15ehttp://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15eTechniquesApproach Summary Licensing status Publication and contact information Drug platforms High throughput synthesis of transcription activator-like effector nucleases (TALENs) A high throughput TALEN synthesis system…Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15fhttp://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15fTechniquesApproach Summary Licensing status Publication and contact information Drug platforms In vivo reprogramming of cardiac fibroblasts into cardiomyocytes In vivo conversion of cardiac fibroblasts into cardiomyocytes…Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15ghttp://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15gTechniquesApproach Summary Licensing status Publication and contact information Drug platforms Structural and biochemical insights into human bromodomain-containing proteins for epigenetic drug discovery Structural and …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15hhttp://www.biocentury.com/scibx/techniques/2012-05-03/the-distillery-techniques-s15hTechniquesApproach Summary Licensing status Publication and contact information Imaging Radiolabeled anti- prostate-specific antigen (KLK3; PSA) antibody for prostate cancer diagnostics A radiolabeled anti-PSA antibody …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10ahttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10aTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Osteoarthritis Filamin A (FLNA); core-binding factor b-subunit (CBFB; CBFb) In vitro and mouse …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10bhttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10bTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) FMS-like tyrosine kinase 3 (FLT3; CD135) Patient sample studies identified …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10chttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10cTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Mitochondria; glycolysis Studies in cell culture suggest combining mitochondrial antioxidants …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10dhttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10dTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Phosphoinositide 3-kinase-b (PI3Kb); PTEN (MMAC1; TEP1) Cell culture and mouse studies suggest …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10ehttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10eTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Phosphoserine aminotransferase 1 (PSAT1) Studies in cell culture suggest inhibiting PSAT1 could help …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10fhttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10fTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7) Mouse studies suggest inhibiting …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10ghttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10gTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Receptor for advanced glycation endproducts (RAGE) In vitro and mouse studies suggest antibodies …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10hhttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10hTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma VEGF; BRAF Studies in mice suggest combined use of metformin and VEGF inhibitors could help treat …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10ihttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10iTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Metabolic syndrome AMP-activated protein kinase (AMPK) In vitro and mouse studies …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10jhttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10jTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Metabolic syndrome Not applicable Studies in mice suggest depleting invariant NK T (…Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10khttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10kTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Metabolic syndrome; obesity MicroRNA-208a (miR-208a) Studies in mice suggest …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10lhttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10lTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Thalassemia Hepcidin antimicrobial peptide (HAMP); transmembrane protease serine 6 (TMPRSS6; matriptase-2…Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10mhttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10mTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) b-Site APP-cleaving enzyme 1 (BACE1); cytochrome P450 3A4 (CYP3A4) Two separate …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10nhttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10nTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Glycogen synthase kinase 3b (GSK3B) Cell culture studies identified pyrazine-…Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10ohttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10oTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Blindness Not applicable Mouse studies suggest transplantation of rod photoreceptor cells could …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10phttp://www.biocentury.com/scibx/therapeutics/2012-05-03/the-distillery-therapeutics-s10pTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Acute lung injury Not applicable Mouse studies suggest bone marrow-derived stromal cells (BMSCs) …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/tools/2012-05-03/tools-evolution-not-revolution-s8http://www.biocentury.com/scibx/tools/2012-05-03/tools-evolution-not-revolution-s8ToolsAn international team has engineered enzymes capable of replicating nucleic acid polymers that are made of unnatural nucleotides. Despite general media reports, the technology is not likely to lead to artificial life …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/translationalnotes/2012-05-03/building-bridges-table-1-trajectories-of-recipients-of-the-california-institute-for-quantitative-biosciences-(qb3)-bridging-the-gap-awards-s4bhttp://www.biocentury.com/scibx/translationalnotes/2012-05-03/building-bridges-table-1-trajectories-of-recipients-of-the-california-institute-for-quantitative-biosciences-(qb3)-bridging-the-gap-awards-s4bTranslational NotesTranslational Notes: Building bridges Table 1. Trajectories of recipients of the California Institute for Quantitative Biosciences' (QB3) Bridging-the-Gap Awards. Principal investigator QB3 campus Award year …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/translationalnotes/2012-05-03/translational-notes-building-bridges-s4ahttp://www.biocentury.com/scibx/translationalnotes/2012-05-03/translational-notes-building-bridges-s4aTranslational NotesJohnson & Johnson has joined the ranks of funders supporting the California Institute for Quantitative Biosciences Bridging-the-Gap Awards by providing two grants for research on an implantable pancreas for type 1 …Thu, 03 May 2012 00:00:00 -0700http://www.biocentury.com/scibx/coverstory/2012-04-26/cover-story-cancer-cell-line-encyclopedias-s1http://www.biocentury.com/scibx/coverstory/2012-04-26/cover-story-cancer-cell-line-encyclopedias-s1Cover StoryTwo research teams have independently developed large-scale screening platforms to profile hundreds of human cancer cell lines and identify drug sensitivity biomarkers. Novartis, a member of one of the groups, is now …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2012-04-26/targets-and-mechanisms-pumping-up-the-metabolic-rev-erb-s6http://www.biocentury.com/scibx/targetsmechanisms/2012-04-26/targets-and-mechanisms-pumping-up-the-metabolic-rev-erb-s6Targets & MechanismsTwo teams have shown that Rev-ERBAs play a central role in regulating the circadian clock and metabolism, and a third group has found that agonizing the receptors treated obesity in mice, suggesting Rev-ERBA agonists …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2012-04-26/targets-and-mechanisms-taus-cease-and-de-cis-t-letter-s8http://www.biocentury.com/scibx/targetsmechanisms/2012-04-26/targets-and-mechanisms-taus-cease-and-de-cis-t-letter-s8Targets & MechanismsResearchers at Harvard Medical School have developed isoform-specific antibodies to target phosphorylated TAU in Alzheimer's disease. The antibodies will need to be validated for early detection, treatment and …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13ahttp://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13aTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Assays & screens Comprehensive cell-line panel for predicting responses to cancer therapies A collection of hundreds…Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13bhttp://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13bTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Assays & screens Comprehensive cell-line panel for predicting responses to cancer therapies A collection of nearly 1…Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13chttp://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13cTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Computational models Computational model for estimating intracranial pressure A computational model for estimating …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13ehttp://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13eTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Dendrimer-based drug delivery to treat cerebral palsy Studies in rabbits identified a dendrimer-small …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13fhttp://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13fTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Imaging Brain tumor imaging via triple-modal MRI, photoacoustic and Raman nanoparticles A triple-modality approach …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13ghttp://www.biocentury.com/scibx/techniques/2012-04-26/the-distillery-techniques-s13gTechniquesThis week in techniques Approach Summary Licensing status Publication and contact information Markers Intercellular adhesion molecule-1 (ICAM-1; CD54) as a marker of treatment response for congenital disorders …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10ahttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10aTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Arachidonate 15-lipoxygenase (ALOX15; 15-LOX) …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10bhttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10bTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Serine/threonine kinase 33 (STK33); heat shock protein 90 (Hsp90) Studies …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10chttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10cTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Phosphoinositide 3-kinase (PI3K) Mouse and cell culture studies suggest …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10dhttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10dTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Glutathione peroxidase 3 plasma (GPX3); tumor protein p53 …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10ehttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10eTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia/reperfusion injury MicroRNA-214 (miR-214) Mouse studies…Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10fhttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10fTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Inositol 1,4,5-triphosphate receptor (ITPR; IP3R) …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10ghttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10gTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Gastrointestinal disease Ceramide A study in mice identified an…Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10hhttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10hTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Chagas disease; leishmaniasis Not applicable An in vitro study …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10ihttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10iTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Dengue fever Dengue virus envelope protein E (DENV_gp1) In vitro …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10jhttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10jTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular dystrophy Heat shock 70 kDa protein 1A (Hsp72; HspA1) …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10khttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10kTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Not applicable In vitro studies suggest gambierol …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10lhttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10lTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia Histone deacetylase 4 (HDAC4) A study in mice suggests blocking the …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10mhttp://www.biocentury.com/scibx/therapeutics/2012-04-26/the-distillery-therapeutics-s10mTherapeuticsThis week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Lysophosphatidic acid receptor 5 (LPAR5; LPA5) Mouse studies suggest …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/translationalnotes/2012-04-26/texas-translation-table-1--cancer-prevention-and-research-institute-of-texas-latest-grant-recipients-s4bhttp://www.biocentury.com/scibx/translationalnotes/2012-04-26/texas-translation-table-1--cancer-prevention-and-research-institute-of-texas-latest-grant-recipients-s4bTranslational NotesTexas translation Table 1. Cancer Prevention & Research Institute of Texas' latest grant recipients. Recipient Program Funding ($M) Companies Asuragen Inc. Mutational profiling of tumors by next-generation DNA …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/translationalnotes/2012-04-26/translational-notes-texas-translation-s4ahttp://www.biocentury.com/scibx/translationalnotes/2012-04-26/translational-notes-texas-translation-s4aTranslational NotesThe taxpayer-backed Cancer Prevention & Research Institute of Texas is moving downstream from its initial focus on basic research in oncology. This month, the institute announced its latest round of grants--this time …Thu, 26 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/coverstory/2012-04-19/cover-story-a-super-kind-of-cytokine-s1http://www.biocentury.com/scibx/coverstory/2012-04-19/cover-story-a-super-kind-of-cytokine-s1Cover StoryResearchers from Stanford and Zurich have engineered a variant of IL-2 that shows a better antitumor response in mice than wild-type IL-2. The new variant, dubbed an IL-2 superkine, is licensed to Teva, which is …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/coverstory/2012-04-19/a-super-kind-of-cytokine-figure1-il-2-regulation-of-t-cells-s3http://www.biocentury.com/scibx/coverstory/2012-04-19/a-super-kind-of-cytokine-figure1-il-2-regulation-of-t-cells-s3Cover StoryA super kind of cytokine Figure 1. IL-2 regulation of T cells. IL-2 binds and signals through a complex consisting of IL-2, IL-2 receptor a-chain (IL2-RA; CD25), IL-2 receptor b-chain (IL2-RB; CD122) and IL-2 …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/targetsmechanisms/2012-04-19/targets-and-mechanisms-blocking-p75-ntr-in-diabetes-s6http://www.biocentury.com/scibx/targetsmechanisms/2012-04-19/targets-and-mechanisms-blocking-p75-ntr-in-diabetes-s6Targets & MechanismsUCSF researchers have shown that genetic deletion of the p75 neurotrophin receptor improves insulin sensitivity in diabetic mice. Targeting this receptor may offer a new way to treat insulin resistance, although the …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-04-19/the-distillery-techniques-s16ahttp://www.biocentury.com/scibx/techniques/2012-04-19/the-distillery-techniques-s16aTechniquesApproach Summary Licensing status Publication and contact information Assays & screens RNA-based molecular diagnostic of infectious diseases Real-time RNA expression profiling of pathogens could provide a rapid …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-04-19/the-distillery-techniques-s16bhttp://www.biocentury.com/scibx/techniques/2012-04-19/the-distillery-techniques-s16bTechniquesApproach Summary Licensing status Publication and contact information Drug platforms RNA-based inhibitors of endogenous antisense transcripts for locus-specific gene upregulation Mouse and cell culture studies …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/techniques/2012-04-19/the-distillery-techniques-s16chttp://www.biocentury.com/scibx/techniques/2012-04-19/the-distillery-techniques-s16cTechniquesApproach Summary Licensing status Publication and contact information Imaging MRI contrast agent targeting vascular cell adhesion molecule-1 (VCAM-1) for detection of early brain metastases VCAM-1-targeting MRI …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10ahttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10aTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL); chronic myelogenous leukemia (CML) Not applicable Cell culture and mouse…Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10bhttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10bTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer NF-kB In vitro and mouse studies suggest dithiolethiones could help treat estrogen receptor (…Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10chttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10cTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer APEX nuclease multifunctional DNA repair enzyme 1 (APEX1) In vitro studies identified APEX1 …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10dhttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10dTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer IL-2; IL-2 receptor a-chain (IL2-RA; CD25); IL-2 receptor b-chain (IL2-RB; CD122) Ex vivo and mouse …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10ehttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10eTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) Cell culture and mouse …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10fhttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10fTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease Purinergic receptor P2Y G protein-coupled 12 (P2RY12; P2Y12) A study …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10ghttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10gTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease Atrial natriuretic peptide (ANP); corin serine peptidase (CORIN) …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10hhttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10hTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Nuclear receptor subfamily 1 group D member 1 (NR1D1; Rev-ERBAa); NR1D2 (Rev-…Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10ihttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10iTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV HCV envelope glycoproteins In vitro and mouse studies have identified mAbs binding to HCV …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10jhttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10jTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV HCV protease Rat and in vitro studies have identified macrocyclic urea-based HCV protease …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10khttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10kTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Viral polymerase In vitro studies have identified a small molecule inhibitor of …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10lhttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10lTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Trypanosome Not applicable In vitro studies suggest terpenes from copaiba oils could help treat …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10mhttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10mTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) b-Amyloid (Ab) Studies in mice suggest monomeric proanthocyanidin metabolites …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10nhttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10nTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) b-Site APP-cleaving enzyme 1 (BACE1) Cell culture studies suggest …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10ohttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10oTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Insulin receptor substrate 1 (IRS1) In vitro, mouse and nonhuman primate studies…Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10phttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10pTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Anxiety; depression Histone deacetylase 6 (HDAC6) Mouse studies suggest inhibiting HDAC6 could help treat…Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10qhttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10qTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Autism Moesin pseudogene 1 antisense (MSNP1AS) Studies in human tissue and in cell culture suggest …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10rhttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10rTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Opioid receptor d1 (OPRD1; DOR) Mouse studies suggest DOR agonists that also promote DOR recycling …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10shttp://www.biocentury.com/scibx/therapeutics/2012-04-19/the-distillery-therapeutics-s10sTherapeuticsIndication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Glaucoma Glycosylation dependent cell adhesion molecule 1 (GLYCAM1) Mouse studies suggest …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/tools/2012-04-19/tools-rna-profiling-pathogens-s8http://www.biocentury.com/scibx/tools/2012-04-19/tools-rna-profiling-pathogens-s8ToolsMassachusetts researchers have developed an RNA-based method for the rapid detection of pathogens in clinical samples. The team is now designing an integrated diagnostic platform that contains a comprehensive set of …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/translationalnotes/2012-04-19/table-1-s4bhttp://www.biocentury.com/scibx/translationalnotes/2012-04-19/table-1-s4bTranslational NotesBuilding tools against autism Table 1. Participants in the European Autism Interventions-A Multicentre Study for Developing New Medications (EU-AIMS) consortium. Academic centers and research organizations …Thu, 19 Apr 2012 00:00:00 -0700http://www.biocentury.com/scibx/translationalnotes/2012-04-19/translational-notes-building-tools-against-autism-s4ahttp://www.biocentury.com/scibx/translationalnotes/2012-04-19/translational-notes-building-tools-against-autism-s4aTranslational NotesAn academic-industry consortium headed by King's College London and Roche launched this month with €29.6 million ($38.9 million) to develop research tools and diagnostics for autism spectrum disorder and to help select …Thu, 19 Apr 2012 00:00:00 -0700